医学
卡铂
佐剂
三阴性乳腺癌
乳腺癌
肿瘤科
彭布罗利珠单抗
免疫疗法
内科学
化疗
癌症
顺铂
作者
Elisa Agostinetto,Laurence Buisseret,Roberto Salgado,Marleen Kok,Michail Ignatiadis
标识
DOI:10.1016/j.annonc.2024.03.003
摘要
The treatment of early triple-negative breast cancer (TNBC) has changed with the results of the pivotal KEYNOTE-522 trial.1 This trial demonstrated that the addition of (neo)adjuvant pembrolizumab to a chemotherapy backbone including taxanes, carboplatin and anthracyclines was associated with a 7.2% absolute improvement in the rate of pathological complete response (pCR) (ypT0/Tis ypN0) and a 9% absolute improvement in the event-free survival (EFS) at a median follow-up of 63.1 months2.
科研通智能强力驱动
Strongly Powered by AbleSci AI